From 396a811f36371656a24083200f2322d2cc28de0c Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Tue, 28 Apr 2026 04:23:58 +0000 Subject: [PATCH] vida: extract claims from 2026-04-28-noom-glp1-companion-biomarker-integration-2025 - Source: inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...20-percentage-points-through-coaching-and-monitoring.md | 7 +++++++ ...04-28-noom-glp1-companion-biomarker-integration-2025.md | 5 ++++- 2 files changed, 11 insertions(+), 1 deletion(-) rename inbox/{queue => archive/health}/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md (98%) diff --git a/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md b/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md index a024ad9cd..3ec4fd100 100644 --- a/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md +++ b/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md @@ -39,3 +39,10 @@ Omada Health's 3x growth in GLP-1 members over 12 months (reaching 150K members) **Source:** Omada Health clinical data, JMIR publication Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 47-49% for standard care, representing a 20-percentage-point improvement. This data is from JMIR-published research and is now validated at commercial scale with 150K+ members in the GLP-1 track as of early 2026. + + +## Extending Evidence + +**Source:** Noom 2025 performance data, Pharmaceutical Commerce + +Noom's microdose GLP-1Rx users showed 77.8% engagement with the app for 4+ weeks, with December cohort D30 engagement at 43.6% (10x+ higher than average health/medical/fitness app retention of 4.3%). The company identified side effect management during titration phase as primary cause of 30%+ dropout in first 4 weeks. Noom's microdose strategy addresses adherence at the biological source (lower dose → fewer side effects) rather than purely behavioral intervention, suggesting that pharmaceutical design innovation may be as important as behavioral support for persistence. diff --git a/inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md b/inbox/archive/health/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md similarity index 98% rename from inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md rename to inbox/archive/health/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md index 4ee817421..eab96c623 100644 --- a/inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md +++ b/inbox/archive/health/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md @@ -7,10 +7,13 @@ date: 2025-12-01 domain: health secondary_domains: [] format: news -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-04-28 priority: medium tags: [noom, GLP-1, behavioral-support, biomarker, digital-health, adherence, microdose] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content